Online inquiry

IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6493MR)

This product GTTS-WQ6493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4366MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ9995MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ3455MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ8935MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ13002MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ15329MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ3768MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ7551MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW